Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00763035 · ClinicalTrials.gov registry record · Early Phase 1
Comparison of Dobutamine and Regadenoson Stress Cardiac Magnetic Resonance (MR)
A Early Phase 1 study, sponsored by Wake Forest University Health Sciences.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 14
- Enrollment target
NCT00763035 is a Early Phase 1 study that was terminated before completion, run by Wake Forest University Health Sciences. The registered enrollment target is 14 participants.
The verdict
NCT00763035, a Early Phase 1 study, was terminated before completion, sponsored by Wake Forest University Health Sciences.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
The goal of this research is to determine the utility of Regadenoson (Lexiscan)for use as an imaging agent with cardiac MR. If found useful, it will help us establish a protocol for regadenoson stress MR perfusion (Regadenoson stress test with cardiac MR).The investigators will compare regadenoson with dobutamine so each participant will undergo two studies. A cardiac MR stress test with regadenoson and with dobutamine. The investigators participants will include patients with history of COPD and Asthma, so it will also help us determine feasibility of Regadenoson in these patient's subgroups.
Interventions
- DRUG Regadenoson
- DRUG Dobutamine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2009-01 |
| Est. Completion | 2011-03 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00763035
The ClinicalTrials.gov registry entry for NCT00763035 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Regadenoson is the first listed.
NCT00763035 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00763035 about?
NCT00763035 is a clinical study titled "Comparison of Dobutamine and Regadenoson Stress Cardiac Magnetic Resonance (MR)". The goal of this research is to determine the utility of Regadenoson (Lexiscan)for use as an imaging agent with cardiac MR. If found useful, it will help us establish a protocol for regadenoson stress MR perfusion (Regadenoson stress test with cardiac MR).The investigators will compare regadenoson w...
What is the current status of trial NCT00763035?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 14 participants. The study started on 2009-01. Estimated completion is 2011-03.
What interventions are being tested in trial NCT00763035?
The interventions under investigation include: Regadenoson (DRUG), Dobutamine (DRUG).
Who is sponsoring clinical trial NCT00763035?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.